548461-82-1 Usage
Uses
Used in Pharmaceutical Industry:
JWH 149 is used as a research compound for studying the endocannabinoid system and its role in various physiological processes. Its high affinity for CB1 and CB2 receptors makes it a valuable tool in understanding the mechanisms of action and potential therapeutic effects of cannabinoids.
Used in Pain Management:
JWH 149 is used as an analgesic agent for managing chronic and neuropathic pain. Its interaction with CB1 and CB2 receptors helps modulate pain signals in the central and peripheral nervous systems, providing relief to patients suffering from various types of pain.
Used in Neurological Disorders:
JWH 149 is used as a potential treatment for neurological disorders such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease. Its ability to bind to CB1 and CB2 receptors may help alleviate symptoms and slow down the progression of these disorders by modulating neuroinflammation and promoting neuroprotection.
Used in Inflammatory Conditions:
JWH 149 is used as an anti-inflammatory agent for treating various inflammatory conditions, including arthritis and inflammatory bowel disease. Its interaction with CB2 receptors helps reduce inflammation and promote tissue repair, offering relief to patients with these conditions.
Used in Appetite Stimulation:
JWH 149 is used as an appetite stimulant for patients with conditions that cause a loss of appetite, such as cancer, AIDS, and anorexia. Its interaction with CB1 receptors in the brain helps stimulate appetite and promote weight gain, improving the overall quality of life for these patients.
Check Digit Verification of cas no
The CAS Registry Mumber 548461-82-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,4,8,4,6 and 1 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 548461-82:
(8*5)+(7*4)+(6*8)+(5*4)+(4*6)+(3*1)+(2*8)+(1*2)=181
181 % 10 = 1
So 548461-82-1 is a valid CAS Registry Number.
548461-82-1Relevant academic research and scientific papers
A novel microwave-irradiated solvent-free 3-acylation of indoles on alumina
Lai, Qiu Yu,Liao, Rong Su,Wu, Shao Yong,Zhang, Jia Xin,Duan, Xin Hong
, p. 4069 - 4076 (2013/12/04)
A simple and efficient 3-acylation of indoles under microwave-heated and solvent-free conditions is developed. This general procedure uses neutral Al2O3 as a new, green and reusable catalyst giving good to high yields within short reaction times. Utilizing such an environmentally- benign methodology, a variety of indoles bearing electron-releasing or electron-withdrawing groups were conveniently acylated.
3-Indolyl-1-naphthylmethanes: New cannabimimetic indoles provide evidence for aromatic stacking interactions with the CB1 cannabinoid receptor
Huffman, John W.,Mabon, Ross,Wu, Ming-Jung,Lu, Jianzhong,Hart, Richard,Hurst, Dow P.,Reggio, Patricia H.,Wiley, Jenny L.,Martin, Billy R.
, p. 539 - 549 (2007/10/03)
A series of 1-pentyl-1H-indol-3-yl-(1-naphthyl)methanes (9-11) and 2-methyl-1-pentyl-1H-indol-3-yl-(1-naphthyl)methanes (12-14) have been synthesized to investigate the hypothesis that cannabimimetic 3-(1-naphthoyl)indoles interact with the CB1 receptor by hydrogen bonding to the carbonyl group. Indoles 9-11 have significant (Ki=17-23 nM) receptor affinity, somewhat less than that of the corresponding naphthoylindoles (5, 15, 16). 2-Methyl-1-indoles 12-14 have little affinity for the CB1 receptor, in contrast to 2-methyl-3-(1-naphthoyl)indoles 17-19, which have affinities comparable to those of 5, 15, 16. A cannabimimetic indene hydrocarbon (26) was synthesized and found to have Ki=26±4 nM. Molecular modeling and receptor docking studies of naphthoylindole 16, its 2-methyl congener (19) and indolyl-1-naphthylmethanes 11 and 14, combined with the receptor affinities of these cannabimimetic indoles, strongly suggest that these cannabinoid receptor ligands bind primarily by aromatic stacking interactions in the transmembrane helix 3-4-5-6 region of the CB1 receptor.
